SymbolBJDX
NameBLUEJAY DIAGNOSTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical/Dental Instruments
Address360 MASSACHUSETTS AVENUE,SUITE 203, ACTON, Massachusetts, 01720, United States
Telephone+1 844 - 327-7078
Fax
Email
Websitehttps://www.bluejaydx.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001704287
Description

Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.

Additional info from NASDAQ:
Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.

2026-09-08 20:50

(85% Positive) BLUEJAY DIAGNOSTICS, INC. (BJDX) Provides Update on systems for federal healthcare distribution

Read more
2026-09-08 10:30

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Read more
2026-08-18 20:16

Director ZEIDMAN FRED S 🟢 acquired 100.0K shares (1 derivative) of Bluejay Diagnostics, Inc. (BJDX) at $2.08 Transaction Date: Aug 17, 2026 | Filing ID: 001127

Read more
2026-08-18 20:16

Director Wurth Douglas Clark 🟢 acquired 100.0K shares (1 derivative) of Bluejay Diagnostics, Inc. (BJDX) at $2.08 Transaction Date: Aug 17, 2026 | Filing ID: 001126

Read more
2026-08-18 20:15

Director Dey Indranil 🟢 acquired 28.0K shares of Bluejay Diagnostics, Inc. (BJDX) Transaction Date: Aug 17, 2026 | Filing ID: 001124

Read more
2026-08-18 20:15

Director CHASE DONALD R 🟢 acquired 100.0K shares (1 derivative) of Bluejay Diagnostics, Inc. (BJDX) at $2.08 Transaction Date: Aug 17, 2026 | Filing ID: 001123

Read more
2026-08-14 11:04

New Form SCHEDULE 13G - Bluejay Diagnostics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003556 <b>Size:</b> 10 KB

Read more
2026-08-13 13:27

New Form SCHEDULE 13G - Bluejay Diagnostics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001493152-26-037644 <b>Size:</b> 11 KB

Read more
2026-08-13 11:56

(70% Positive) BLUEJAY DIAGNOSTICS, INC. (BJDX) Announces Enrollment Update for million Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Read more
2026-08-13 10:00

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07425587 Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study Sepsis, Septic Shock Recruiting 2026-05-04 2026-12-30 ClinicalTrials.gov
NCT06654895 Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study Sepsis, Septic Shock Active_Not_Recruiting 2024-11-12 2026-09-30 ClinicalTrials.gov
NCT06181604 Multicenter Symphony IL-6 Monitoring Sepsis ICU Study Sepsis Completed 2024-01-12 2024-07-12 ClinicalTrials.gov
NCT05665153 Symphony IL-6 Study in Patients at Risk of Severe Sepsis Severe Sepsis Unknown 2022-11-22 2024-11-21 ClinicalTrials.gov
NCT05048888 Symphony IL-6 Reference Range Study Sepsis Unknown 2021-08-31 2024-03-30 ClinicalTrials.gov
NCT05060250 Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis … Severe Sepsis Unknown 2021-08-31 2024-12-31 ClinicalTrials.gov
NCT05048927 Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis Severe Sepsis Unknown 2021-08-31 2024-12-31 ClinicalTrials.gov
Total clinical trials: 7